Atlas Trials

QED Therapeutics, a BridgeBio company

11 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch QED Therapeutics, a BridgeBio company

RecordFirmDate
Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia (NCT07393373)QED Therapeutics, a BridgeBio company2026-04-23
Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH) (NCT07169279)QED Therapeutics, a BridgeBio company2025-11-19
An Interventional Study of Infigratinib in Children With Hypochondroplasia (NCT06873035)QED Therapeutics, a BridgeBio company2025-04-22
Prospective Clinical Assessment Study in Children With Hypochondroplasia (NCT06410976)QED Therapeutics, a BridgeBio company2024-06-05
Extension Study of Infigratinib in Children With Achondroplasia (ACH) (NCT05145010)QED Therapeutics, a BridgeBio company2021-12-06
Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (NCT04197986)QED Therapeutics, a BridgeBio company2020-03-11
Study of Infigratinib in Children With Achondroplasia (NCT04265651)QED Therapeutics, a BridgeBio company2020-03-10
Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations (NCT03773302)QED Therapeutics, a BridgeBio company2019-12-27
Prospective Clinical Assessment Study in Children With Achondroplasia (ACH) (NCT04035811)QED Therapeutics, a BridgeBio company2019-08-12

Track QED Therapeutics, a BridgeBio company automatically

Every clearance here is in the API, with alerts when new ones post.